API | sulfametopyrazine

sulfametopyrazine Report issue

Small molecule Experimental

AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW

Sulfalene or sulfametopyrazine (BAN) is a long-acting sulfonamide antibacterial used for the treatment of chronic bronchitis, urinary tract infections and malaria. As of 2014 there were only two countries in which it is currently still marketed: Thailand and Ireland. ^Wikipedia

Chemistry

SMILES: OC(=O)CCC(=O)NC1=CC=C(C=C1)S(=O)(=O)NC2=NC=CS2
InChIKey: SKVLYVHULOWXTD-UHFFFAOYSA-N
Mol. Mass: 355.389
ALogP: 1.75 Partition coefficient
ChEMBL Molecules:

succinylsulfathiazole

sulfalene

sulfamethoxypyridazine

More Chemistry

Pharmacology

Mechanism of Action:
- 7,8-dihydro-6-hydroxymethylpterin pyrophosphokinase-dihydropteroate synthase (Plasmodium falciparum) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

Organizations (5)

Research & Development (5)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (3)

Malaria, Falciparum (Phase 3)

Schistosoma haematobium (Phase 2/Phase 3)

Schistosoma mansoni (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 3
# of Trial Organizations: 5

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue